

**DATASHEET**

Version 20181206

**IL-21, Human****Cat. No.:** Z02715-10**Size:** 10.0 ug**Synonyms:** Interleukin-21 (IL-21), Human;**Description:**

IL-21 is a pleiotropic cytokine produced by CD4+ T cells in response to antigenic stimulation. Its action generally enhances antigen-specific responses of immune cells. The biological effects of IL-21 include induction of differentiation of T-cells-stimulated B-cells into plasma cells and memory B-cells, stimulation (in conjunction) with IL-4 of IgG production, and induction of apoptotic effects in naïve B-cells and stimulated B-cells in the absence of T-cell signaling. Additionally, IL-21 promotes the anti-tumor activity of CD8+ T-cells and NK cells. IL-21 exerts its effect through binding to a specific type I cytokine receptor, IL-21R, which also contains the gamma chain ( $\gamma$ c) found in other cytokine receptors including IL-2, IL-4, IL-7, IL-9 and IL-15. The IL-21/IL-21R interaction triggers a cascade of events which includes activation of the tyrosine kinases JAK1 and JAK3, followed by activation of the transcription factors STAT1 and STAT3.

**Amino Acid Sequence:**

00001 QGQDRHMIRM RQLDIVDQL KNYVNDLVPE FLPAPEDVET  
00041 NCEWSAFSCF QKAQLKSANT GNNERIINVS IKKLKRKPPS  
00081 TNAGRRQKHR LTCPSCDSEY KKPPKEFLER FKSLQKMIH  
00121 QHLSRTHGS EDS

**Source:** *E. coli***Species:** Human

**Biological Activity:** Fully biologically active when compared to standard. The  $ED_{50}$  as determined by a cell proliferation assay using human N1186 T cells is less than 20 ng/ml, corresponding to a specific activity of  $> 5.0 \times 10^4$  IU/mg.

**Molecular Weight:** Approximately 15.4 kDa, a single non-glycosylated polypeptide chain containing 133 amino acids.

**Formulation:** Lyophilized from a 0.2  $\mu$ m filtered concentrated solution in PBS, pH 7.4.

**Appearance:** Sterile Filtered White lyophilized (freeze-dried) powder.

**Reconstitution:** We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at  $\leq -20$  °C. Further dilutions should be made in appropriate buffered solutions.

**Purity:**  $> 97$  % by SDS-PAGE and HPLC analyses.

**Endotoxin Level:** Less than 1 EU/ $\mu$ g of rHuIL-21 as determined by LAL method.

**Storage:** This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles.